Back to GSKView full pipeline
Phase 3
Development Phase
2
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
Upcoming Catalysts
What are catalysts?Competitive Landscape
0 competitors in Primary Myelofibrosis
View Full LandscapeDrug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA1/25/2024
Omjjara
Omjjara is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.
Orphan
View on EMADrug Science
Mechanism of action & safety profile
Related Pipeline
Daprodustat smallPhase 3
Anaemia
diphtheria, tetanus, pertussis & Hib vaccinePhase 3
Tetanus
Rosiglitazone (BRL49653C)Phase 3
Diabetes Mellitus, Type 2
GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)Phase 3
Herpes Zoster
Ropinirole prolonged releasePhase 3
Parkinson Disease
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts